Literature DB >> 9213056

Management of glioblastoma multiforme: with special reference to recurrence.

R Durmaz1, S Erken, A Arslantaş, M A Atasoy, C Bal, E Tel.   

Abstract

Between 1985 and 1995, 46 patients underwent craniotomy for glioblastoma multiforme. The mean age was 47, varying from 9 to 71 years. The influence of such prognostic factors as age, preoperative Karnofsky score, extent of resection, tumour site, tumour size, radiotherapy, reoperation as well as initial symptoms upon survival were studied. Of these, gross complete removal, radiotherapy, preoperative Karnofsky score, and reoperation were shown to be statistically significant to the survival time according to logrank and univariate tests. However, age, preoperative Karnofsky score, tumour size and temporal localisation remained as significant factors in multivariate analysis. The overall median survival was 53 weeks, with no patients surviving more than 3 years. Of the patients, 41% survived over a year and 8.6% lived over two years. Twenty-six patients developed a recurrent mass after an interval of 32 weeks. The median interval time from operation to recurrence was longer in those patients who underwent gross removal than in those who had a subtotal resection, 28.2 against 20 weeks (P < 0.05). Of patients who had a recurrent mass, 16 were reoperated on, with a subsequent median survival time of 26.5 weeks. Our experience suggests that the survival of patients with glioblastoma depends on many factors, including radical surgery as an initial step. In addition, the gross total removal of the tumour also delays the development of recurrence.

Entities:  

Mesh:

Year:  1997        PMID: 9213056     DOI: 10.1016/s0303-8467(97)00014-0

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  16 in total

1.  Novel Surgical Approaches to High-Grade Gliomas.

Authors:  Fahid Tariq Rasul; Colin Watts
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

2.  Should we reoperate for recurrent high-grade astrocytoma?

Authors:  Jin-fang Xu; Jun Fang; Yi Shen; Jian-min Zhang; Wei-guo Liu; Hong Shen
Journal:  J Neurooncol       Date:  2011-05-17       Impact factor: 4.130

3.  Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy.

Authors:  K L Chow; Y P Gobin; T Cloughesy; J W Sayre; J P Villablanca; F Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  2000-03       Impact factor: 3.825

4.  Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection.

Authors:  J Shinoda; N Sakai; S Murase; H Yano; T Matsuhisa; T Funakoshi
Journal:  J Neurooncol       Date:  2001-04       Impact factor: 4.130

5.  Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas.

Authors:  Ali Arslantas; Sevilhan Artan; Ulkü Oner; M Hamza Müslümanoglu; Muhsin Ozdemir; Ramazan Durmaz; Didem Arslantas; Murat Vural; Erhan Cosan; Metin Ant Atasoy
Journal:  Pathol Oncol Res       Date:  2007-03-27       Impact factor: 3.201

6.  The importance of genomic copy number changes in the prognosis of glioblastoma multiforme.

Authors:  Ali Arslantas; Sevilhan Artan; Ulkü Oner; Hamza Müslümanoğlu; Ramazan Durmaz; Erhan Cosan; Metin Ant Atasoy; Nurettin Başaran; Eşref Tel
Journal:  Neurosurg Rev       Date:  2003-07-04       Impact factor: 3.042

7.  Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.

Authors:  Francesca Nava; Irene Tramacere; Andrea Fittipaldo; Maria Grazia Bruzzone; Francesco Dimeco; Laura Fariselli; Gaetano Finocchiaro; Bianca Pollo; Andrea Salmaggi; Antonio Silvani; Mariangela Farinotti; Graziella Filippini
Journal:  Neuro Oncol       Date:  2014-01-23       Impact factor: 12.300

8.  Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas.

Authors:  Antonio Silvani; Paola Gaviani; Anna Fiumani; Vidmer Scaioli; Elena Lamperti; Marica Eoli; Andrea Botturi; Andrea Salmaggi
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

9.  Hypofractionated stereotactic reirradiation for recurrent glioblastoma.

Authors:  Gozde Yazici; Mustafa Cengiz; Gokhan Ozyigit; Gulnihan Eren; Ferah Yildiz; Fadil Akyol; Murat Gurkaynak; Faruk Zorlu
Journal:  J Neurooncol       Date:  2014-07-11       Impact factor: 4.130

10.  Replenishable drug depot to combat post-resection cancer recurrence.

Authors:  Yevgeny Brudno; Matthew J Pezone; Tracy K Snyder; Oktay Uzun; Christopher T Moody; Michael Aizenberg; David J Mooney
Journal:  Biomaterials       Date:  2018-05-06       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.